The transplant literature is replete with recommenda-reasonable to suggest that manipulation of immunosuptions regarding the choice of immunosuppressive medipression will make the kidney from a 65-year-old hypercations for the prevention and treatment of acute rejectensive victim of a cerebrovascular event that suffered tion, and, with somewhat less conviction, for long-term delayed graft function will perform as well as a kidney maintenance immunosuppression [1] . The question posed from a 20-year-old trauma victim that functioned immein the title, however, has been given minimal attention.
diately. Much of the long-term behavior of a graft can It is of great practical importance, and it is one of the be predicted by its pretransplant features and its early most frequent questions posed to me by my nephrology post-transplant function without relating to the specifics colleagues responsible for the long-term care transplant of the immunosuppressive cocktail [7] . of recipients. The discussion that follows will relate principally to the immunosuppressive management of the fail-QUESTIONS TO ADDRESS BEFORE ing kidney transplant. The broader diagnostic and man-MANIPULATING IMMUNOSUPPRESSION agement issues have been reviewed extensively elsewhere.
The question of adjusting the immunosuppressive regimen for patients with chronic allograft dysfunction may CHRONIC REJECTION OR CHRONIC often be the first that is asked of me by my colleagues, ALLOGRAFT NEHROPATHY?
but it is not necessarily the best question to ask. Chronic Semantics are important since the words we choose allograft failure is essentially a specialized form of chronic to describe a clinical problem may influence the manner renal failure and should be approached with a similar in which we try to address it. The clinical syndrome is philosophy. Pre-renal and post-renal reversible causes familiar: Starting months to years after transplantation, must be ruled out, the volume status must be optimized, an initially stable patient begins to develop progressive and the medication regimen critically assessed. In most loss of renal function reflected by a rising serum crepatients, the diagnosis will be confirmed by biopsy which atinine and associated with hypertension and varying also serves to uncover the cases of recurrent or de novo degrees of proteinuria [2] . If an allograft biopsy is perglomerulonephritis that may account for up to 5% of longformed irreversible structural changes are found, including term graft losses. A biopsy also permits a diagnosis of glomerulosclerosis, interstitial fibrosis and atrophy, and less common but critical-to-diagnose causes of graft failvascular hyalinosis. There may also be patchy interstitial ure such as post-transplant lymphoma and polyoma virus infiltrates and evidence of calcineurin inhibitor (CI) toxnephropathy [8] . Recent changes in immunosuppressive icity [3] . The clinical course is often unpredictable [4] . drug formulations (e.g., from Sandimmune cyclosporine The term "chronic rejection" suggests that the alloimto Neoral cyclosporine) may cause graft dysfunction, as mune etiology of the process is primary and hence may may the addition to the medication regimen of drugs be susceptible to immunosuppressive therapy. The term that interact with the hepatic metabolism of the CIs [9]. "chronic allograft nephropathy" (CAN) may be less satisfying to the purist. but it at least reflects the multiple factors, both ostensibly immune [5] and non-immune [6], WHAT IS THE APPROPRIATE DOSE OF THE that have been shown to predict the syndrome. It is un-
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dose regimens of these drugs for long-term use in well-episodes designated as acute rejection that were typically mild or borderline and responsive to a short course of functioning grafts, let alone in poorly functioning grafts. Most of the standard recommendations for well-func-high-dose steroids. No patient was deemed to require reintroduction or escalation of the CI dose. In a follow-tioning grafts are based on retrospective analyses. There is also a considerable, though disputed, body of evidence up analysis of this data, the authors concluded that cyclosporine withdrawal was the most beneficial policy for that it may be safe to discontinue these drugs completely in many patients, though most practitioners seem to have the management of CAN (abstract A4816, ASN/ISN World Congress of Nephrology, October 2001). It should determined that the risk/benefit analysis favors their continuation [1]. The nephrotoxic potential of the CIs is well be emphasized. however, that the various treatment groups varied in their baseline characteristics and were established and, although their use is conducive to excellent long-term function, some degree of renal dysfunction, not prospectively randomized, and that only 13 patients were totally withdrawn from CI drugs. Graetz et al (ab-both reversible and irreversible, is an inevitable consequence of their administration [7] . In the case of CAN, stract A4663, ASN/ISN World Congress of Nephrology, October 2001) replaced cyclosporine with MMF in a the situation is particularly paradoxical. Is it logical to continue these drugs, both vasoconstrictors, in the face group of 15 patients with CAN and reported a significant improvement in the serum creatinine level without graft of fibrosis and vascular hyalinosis for which they may be in varying degrees responsible? On the other hand, should loss or episodes of acute rejection. Similar findings were reported by Filler et al [12] in a small group of pediatric their use be intensified to address any undertreated alloimmune response that the histologic picture may sug-patients with progressive graft dysfunction ascribed to cyclosporine toxicity. gest? A theoretical argument could be made for both dose reduction and intensification.
Based on this data, CI dose reduction in CAN appears to be safe and well tolerated and to have a beneficial There is no substantive evidence to suggest that CAN will respond favorably to intensification of CI dosage, effect on the rate of deterioration of graft function in to exchanging CIs, or to changing formulations of CIs. a high percentage of patients. Not all patients benefit, On the contrary, each of these manipulations may be however, and the occurrence of episodes of acute rejecfollowed by apparent transient or permanent deterioration indicates that careful follow-up is mandatory. It is tion of function, presumably as a result of exaggeration also important to note, as emphasized by Kreis et al [13] of vasocontriction and nephrotoxity [9] . There is, howthat functional stability or improvement as judged by ever, a body of evidence suggesting that reduction or the serum creatinine level may not necessarily parallel discontinuation of these drugs may be beneficial and, in histologic stability. this regard, the studies of Weir et al [10, 11] are worthy of particular attention. Starting in 1996, Weir et al [10] MYCOPHENOLATE MOFETIL FOR began a policy of reducing the CI dose in patients with CHRONIC REJECTION declining renal function and biopsy proven CAN. So-MMF was introduced into clinical transplantation called immunosuppressive "support" was maintained by based on its capacity to reduce the incidence of acute addition of mycophenolate mofetil (MMF) or by increasrejection in the early post-transplant period [1]. There ing its dose. Early observations demonstrated a shortwere also theoretical reasons, based on studies in animal term benefit in the rate of loss of renal function the models [14] , to anticipate that the drug might serve to authors suggested was caused by a release of CI induced prevent or treat clinical CAN. Convincing proof of ability vasoconstriction. The long-term impact of this policy was to do so, however, has proved elusive, though the availthen evaluated in a cohort of 118 patients followed over able data is suggestive. In the prospective studies of a period of approximately 2 years [11] . Once again, MMF prophylactic MMF use there was a small but not statistiwas continued or added together with low-dose steroids. cally significant reduction in the rate of graft loss [15] . The decision to discontinue the CI rather than reduce It should be noted, however, that the studies were not its dose (typically to approximately 50% of its initial designed or statistically powered to address long-term value) was made in only 18 patients in somewhat arbifunction [1, 15] . In a large retrospective study, Ojo et al trary manner based on HLA matching and the degree [16] showed that use of MMF at some time during the of renal dysfunction. Depending on the technique used post-transplant course was associated with a lower incito determine the rate of change of renal function followdence of chronic rejection, but the extent of MMF treating the change in CI dose, more than 90% of the disconment to achieve this effect could not be determined. tinued group and 40% of the reduced group showed an None of these studies, however, address the issue of improvement or at least a lack of deterioration in the whether MMF has a favorable impact on established rate of decay of renal function. Thirty-three of the pa-CAN. In a small, randomized study by Glicklich et al tients were biopsied during follow-up to evaluate episodes of graft dysfunction and there were a total of 19 [17] , no benefit could be shown for the addition of MMF in a study of 30 repeated with randomization to groups receiving or not patients with CAN found no benefit in adding rapamycin receiving MMF. Until these data are available, it would to a reduced dose of cyclosporine. In this study, rapaseem reasonable to introduce MMF or continue its admycin was introduced while reducing but not discontinuministration if the dose of CI is significantly reduced.
ing the CI dose, and it is possible that the potential benefits of rapamycin were masked by continued CI toxicity [18] . Hyperlipidemia may be exaggerated by the RAPAMYCIN FOR CHRONIC REJECTION addition of rapamycin and may theoretically be a factor The histology of CAN together with work on experiin the perpetuation of CAN [24] . It would seem logical mental models of chronic rejection provide a tempting that if the potential benefits of rapamycin in CAN are to theoretical rationale for the benefits of rapamycin in be exploited, the drug should be studied in this situation CAN. These benefits have yet to be proven of clinical together with discontinuation or drastic dose reduction value [18] . Rapamycin inhibits growth factor mediated of the CI. proliferation of cells involved in the pathogenesis of chronic rejection in vitro [19, 20] . In a variety of experi-MANAGEMENT OF CAN WITH A mental models, rapamycin reduced intimal hyperplasia FLUCTUATING CREATININE LEVEL resulting from both immune and non-immune injury [18, 21] . The doses of rapamycin used in these studies During the course of CAN, there may be fluctuations are, however, considerably greater than those used cliniin the serum creatinine level whose clinical significance cally. Of particular importance rapamycin, in standard may be difficult to assess. Ideally, a full clinical, ultrasonclinical dosage, has a immunosuppresssive potency apographic, and histologic evaluation would accompany proaching that of the CIs, but it is not nephrotoxic when each of these events, though patients and physicians may used alone [18] .
be understandably reluctant repeatedly to biopsy pa-In a large, multicenter, randomized study, the discontients with established CAN and empiric decisions may tinuation of cyclosporine in stable patients with good be required. With respect to the immunosuppression regigraft function receiving rapamycin was shown to be safe men, care must be taken to ensure patient adherence, and to be associated with significant improvement in lack of which could predispose to superimposed acute graft function [22] . The obvious question, therefore, is rejection episodes. The current availability of multiple, whether this benefit can be safely reproduced in patients similar but not identical, preparations of cyclosporine with impaired graft function and, if so, whether any benerequires that inquiry be made of the patient to determine fit is transient and likely to be hemodynamic in nature, if a new formulation had been prescribed with a potenor long-lasting and likely histologic in nature. Adequate tially different pharmacologic profile. It may be tempting data to answer this question is lacking, though the availto treat otherwise unexplained episodes of rising creatiable preliminary data is encouraging. Dominguez The above discussion has related to the management of patients with CAN in whom graft function is still re-23 patients with varying degrees of CAN found that graft function improved when rapamycin was substituted for garded as salvageable. In CAN as in native kidney chronic
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renal failure, a point is eventually reached when prepara-2. Consideration should be given to reduction or even tions for end-stage failure must be made. In the case of discontinuation of CI therapy. Such a therapeutic CAN, the question of how to manage the immunosupmaneuver requires careful follow-up to screen for pressive regimen in the abandoned graft must be adepisodes of deteriorating graft function. dressed. Ideally, the patient with the failed graft returns 3. Reduction of CI therapy is generally accompanied to dialysis (or receives another transplant) without the by addition of a non-nephrotoxic immunosuppresnecessity to remove the failed graft which typically besant, though it has not been firmly established that comes small and fibrotic. Once a decision has been made such addition is necessary. There is most experience to abandon a graft, it has been my policy to discontinue with MMF in these circumstances, though rapamiadjunctive immunosuppressive agents (e.g., azathioprine, cin may be an appropriate alternative. MMF) and to maintain low plasma levels of the CI until 4. Introduction of a new immunosuppressive agent in dialysis commences at which time they are stopped compreviously immunosuppressed patients has potenpletely over several weeks. If a patient is still receiving tially dangerous consequences. Patients should be corticosteroids, the dose should be minimized and then monitored carefully, and consideration given to discontinued slowly over several months because the prophylaxis to prevent development of infectious patient may be adrenally suppressed. During the process complications. of immunosuppressive withdrawal, the failed graft may 5. High baseline doses of corticosteroids are not indibecome a source of constitutional symptoms (swelling, cated. "Pulse" steroid therapy may be valuable for fever, local pain, and hematuria) that require treatment. episodes of deteriorating function, but repeated In this event, a short course of oral or intravenous corticotreatment should be avoided. Ideally, use of pulse steroids may reverse the symptoms and signs. The corticosteroids in these circumstances should follow histosteroid dose, however, should be rapidly returned to its logic confirmation of an element of acute rejection. baseline level and, if the clinical manifestations return, 6. Since repeated pulse steroid therapy should be then allograft nephrectomy may be required. The cortiavoided, it is rarely indicated to repeatedly biopsy costeroid dose should not remain elevated, and other patients with established CAN. immunosuppressive agents should not be reintroduced.
7. If graft function continues to deteriorate despite Patients are sometimes reluctant to discontinue immunothe above measures, plans should be made to presuppression after returning to dialysis for fear of losing pare for ESRD treatment options, and immunosupresidual graft function and urine output. They should pression should be withdrawn in a stepwise fashion be persuaded that the risks associated with continued as when dialysis commences. immunosuppression while on dialysis are not worth the marginal benefit of the residual function. 
